(Reuters) - The U.S. District Court for the Southern District of New
York ruled on Tuesday that the patent is invalid, the company
said in a statement. Following the FDA approval, Perrigo will
begin marketing Famotidine, it added.
Read more at Reuters.com Government Filings News
York ruled on Tuesday that the patent is invalid, the company
said in a statement. Following the FDA approval, Perrigo will
begin marketing Famotidine, it added.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment